Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
about
Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeuticsChemoresistance and Cancer-Related Inflammation: Two Hallmarks of Cancer Connected by an Atypical Link, PKCζNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewThe oncogenic role of Yin Yang 1Correlation of the expression of YY1 and Fas cell surface death receptor with apoptosis of peripheral blood mononuclear cells, and the development of multiple organ dysfunction in children with sepsis.Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasUsing functional genomics to overcome therapeutic resistance in hematological malignancies.Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression.Glycogen synthase kinase-3β, NF-κB signaling, and tumorigenesis of human osteosarcoma.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamicsTumor-suppressing function of caspase-2 requires catalytic site Cys-320 and site Ser-139 in mice.Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects.Transcription regulator Yin-yang 1: from silence to cancer.Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study.Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma.Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.What signals are generated by anti-CD20 antibody therapy?TRAF6 activation in multiple myeloma: a potential therapeutic targetPostulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.Rituximab: modes of action, remaining dispute and future perspective.RKIP-mediated chemo-immunosensitization of resistant cancer cells via disruption of the NF-κB/Snail/YY1/RKIP resistance-driver loopGene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma.Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.Array of translational systems pharmacodynamic models of anti-cancer drugs.Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Hypoxia inducible factor-1α induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL.Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP.Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells.Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis.Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis.Suitability of Yin Yang 1 transcript and protein levels for biomarker studies in B cell non-Hodgkin lymphoma.RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact
P2860
Q26782525-6D44CCA2-00CC-40F4-9B1C-269A6B6FA6D6Q26853683-6CA03AAC-CD19-4F5D-8223-089DC6469DF6Q27304386-28B31D62-8684-47FC-A5BB-256F2CE554BCQ28385924-F1F1FA5E-B022-42D7-BF62-8CF4A07B28F2Q33670949-C8BE023B-E5B9-469B-A45A-46C0E02B54A2Q34369841-B7CBC9AF-5A79-498E-961C-95E698768015Q34401328-A7BC5E01-7F19-4803-84C7-B9F086B3AC4FQ34564852-570C1008-05AF-491B-8CC8-3C1151E6EDDCQ34637826-A9C92864-F228-4697-B605-10AB3D63A8D0Q34700655-A736D2BE-4BD5-4CB1-AF85-83814EEBD79CQ35919697-F552482A-E0E6-4F64-AC97-F068DEB8F3FBQ35922424-86F1F47C-253A-4E92-A867-26FA01A0F13FQ36157946-8D9ECED0-1E2C-4F58-8D46-D2233D38B9C3Q36350378-A3FF33AA-2E22-4DEB-81E3-1F16E70CA00FQ36524079-FBA4FAA6-14E1-4D20-B8E8-EE15682D130FQ36832106-FA59AD04-4EC8-44F8-A5E2-070C6EF848ECQ37183688-E60D55E2-782B-401C-86CF-239312A74D5CQ37262987-31DAA5F3-F3C0-4C64-86B7-601ACA61A41CQ37738409-725CA0DB-E222-4579-BD66-73854F678C45Q37996112-BFF036F8-FE9B-44E5-86E3-F0549D94BB6FQ38273851-EB4265B3-BF65-47A8-8977-47BAE046757EQ38294619-5ECC6841-6CA5-4F7E-B7A3-A8A509EE825DQ38322277-6E56F5BC-FDE4-4573-BC66-6A20D98ABCDDQ38480261-DA1750DD-1682-4E5A-8F3D-C9352DBCD671Q38962519-B0423946-2037-4EA6-964F-DC5E4739ED6FQ38988505-F34B541E-8C2C-465C-B1C1-67001900B3CBQ38988648-C728A0B5-0307-4B4B-B0E4-93A7941317C6Q39013616-F7DF7998-0E13-41D4-902B-3256D8CCC1B5Q39271109-0589BAC7-9BC9-4019-9206-8FF231C58BE2Q39621015-0393E823-F22C-40E5-ADDB-62620105A6DDQ39990380-8A46DF85-7A0A-48F7-B844-CAEC885863FFQ43196809-0857D65F-3518-4131-9A5D-0A99560B3E53Q43298313-CAE93A56-51A6-46E1-BEAE-D7CFC2BE1D8AQ53755708-AE32151B-6274-4F6E-B885-E756D0ECC1F4Q53755710-667A26D0-34C2-4A5D-8C41-DAEB560B3646Q55322225-3D42A6CD-7575-47AC-9384-48FB5B2DE777Q58704356-64828A3D-1196-476B-BF1D-0E604916037A
P2860
Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Rituximab-induced inhibition o ...... chemoresistance, respectively.
@en
type
label
Rituximab-induced inhibition o ...... chemoresistance, respectively.
@en
prefLabel
Rituximab-induced inhibition o ...... chemoresistance, respectively.
@en
P2093
P1476
Rituximab-induced inhibition o ...... chemoresistance, respectively
@en
P2093
Ali R Jazirehi
Benjamin Bonavida
Sara Huerta-Yepez
P304
P356
10.4049/JIMMUNOL.175.4.2174
P407
P577
2005-08-01T00:00:00Z